Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9150579 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
US10570142 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
US9969740 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(12 years from now) | |
US10414773 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9669033 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
US10981919 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
US10072013 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(10 years from now) | |
US10947244 | TG THERAPS | Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations |
May, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 5, 2026 |
Drugs and Companies using UMBRALISIB TOSYLATE ingredient
NCE-1 date: February, 2025
Market Authorisation Date: 05 February, 2021
Treatment: Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; Relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic